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Background: In a previous study we identified 3 different gait patterns in a group of children with CMT1A disease:
Normal-like (NL), Foot-drop (FD), Foot-drop and Push-off Deficit (FD&POD). Goal of the present study was to
perform a follow-up evaluation of the same group of patients to analyze possible changes of gait features in
relation to disease progression or specific therapy.
Methods: Nineteen children with CMT1A were evaluated clinically (CMT-Examination Score and Overall Neuropathy
Limitation Scale) and through gait analysis 18.2±1.5 months after a baseline evaluation. Meanwhile, 3 of them had
foot surgery.
Results: Fifteen out of the 16 non-operated patients significantly changed at least one of the two parameters
associated to primary signs (FD and/or POD). Eleven participants worsened at least one parameter and 9 improved
one parameter. CMTES significantly worsened for the group of non-operated patients. However, there was no
change in CMTES score in 4 patients and in ONLS score in 11. At subgroup level, participants originally belonging
to NL group showed a trend towards a foot-drop deficit (−15%, ns); FD and FD&POD subgroups did not change
their primary signs, although significant changes were identified individually. All 3 patients operated have improved
push-off and proximal joint patterns during walking. Clinical scores did not change within any sub-group.
Conclusions: Subtle changes occurring in 1.5 year in gait features of CMT1A children can be instrumentally
identified. Such changes show a large inter-subject variability, with some patients even improving their walking
pattern. There is anecdotal evidence that foot surgery may improve the push-off phase of gait.
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Follow-upBackground
Charcot-Marie-Tooth type 1A (CMT1A), an inherited de-
myelinating neuropathy, is the most common hereditary
neuropathy (40-50% of all CMT cases). It is characterized
by length-dependent degeneration of the motor and sen-
sory fibres with consequent weakness of distal limb mus-
cles, distal sensory loss and foot deformities [1]. Usually,
symptoms start in childhood and then slowly progress
centripetally, from the intrinsic foot muscles to the leg* Correspondence: mferrarin@dongnocchi.it
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reproduction in any medium, provided the ormuscles, thus affecting locomotor functions. Several clin-
ical and neurofunctional measures have been proposed
[2–5] to monitor the progression of impairment, disability
and quality of life in CMT patients. However, standardized
measures for routinary clinical evaluation of the pediatric
CMT population are lacking [3,6] and only recently a
pediatric scale was proposed, validated and its responsive-
ness is in progress [7].
Gait analysis has been used to objectively classify walk-
ing patterns in adults [8,9] and children [10] with CMT
disease. These studies identified CMT-related typical gait
abnormalities, i.e. foot-drop and push-off deficit, and
consequent locomotor strategies to compensate for suchl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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functional efficacy of different orthoses for adults with
CMT [11], finding that specific orthotic management may
control effectively foot-drop and increase gait speed, be-
sides improving compliance with respect to standard
Ankle Foot Orthoses.
Longitudinal studies of CMT disease are important to
analyze the progression of the disease, to improve the
accuracy of prognosis and to better assess the efficacy of
new therapy in intervention studies [1]. A few prospect-
ive natural history studies are reported in literature de-
scribing a slow progression of impairment and disability
in CMT1A [2,12,13].
However, to our knowledge, no longitudinal study on
CMT patients using gait analysis has been published yet,
although it was shown to be a useful tool in longitudinal
studies both on normal children during growing [14]
and on pathological cases, for instance patients after
total knee replacement [15] or children with Cerebral
Palsy to evaluate the natural progression of gait [16].
In a previous study [10] on a group of 21 children with
CMT1A we identified 3 different gait patterns, through
a cluster analysis technique on gait analysis parameters
related to primary signs (foot-drop and push-off deficit).
Accordingly, participants were classified as 1) normal-
like (NL), when no primary gait deviations were de-
tected; 2) patients with foot-drop (FD), when the only
significant alteration with respect to controls was the
deficit of ankle dorsiflexion during swing; 3) patients
with foot-drop and push-off deficit (FD&POD), when a
significant reduction of plantarflexion power at push-off
was evidenced in addition to foot-drop. Patients belonging
to the NL subgroup showed ankle dorsiflexion deficit dur-
ing heel-walking. The FD&POD subgroup was associated
to a significantly worse clinical score.
Aim of this study was to perform a 1.5 year follow-up
assessment on the same group of CMT1A young pa-
tients to verify whether changes in locomotor functions
due to disease progression or to specific therapies were
detected by gait analysis techniques and to describe their
possible correlation with changes in clinical scores.
Moreover, we aimed to test whether the progression of
this degenerative condition was associated to the shift of
patients towards more severe gait pattern classification.
Methods
Participants
The group analyzed in the present study consisted of
nineteen children with CMT1A (9 females, 10 males;
mean±SD: age 11.8±2.8 years; body mass 43.0±12.1 kg;
height 151±15 cm; CMTES a 4.0±2.5; ONLS b 2.0±1.0;
time from first clinical symptoms: 7.3±3.8 years) all be-
longing to the group considered in the baseline study [10].
Inclusion criteria for the baseline study were age < 18 yrs,diagnosis of CMT1A based on clinical and genetic criteria.
Exclusion criteria were presence of other neurological dis-
eases or unrelated clinical conditions affecting locomotor
functions; inability to walk unaided barefoot; previous
double or triple arthrodesis of the rear foot joints.
Of the original twenty-one children included in the
baseline study, two (one originally belonging to the NL
subgroup and one to the FD subgroup) could not
be reassessed, three (all originally belonging to the
FD&POD subgroup) underwent foot surgery between
the baseline and the follow-up evaluation and will be
discussed separately, the other sixteen allowed for the
study of the disease natural progression. The average
time between baseline and follow-up evaluations was
18.2±1.5 months.
Data from eighteen healthy age-matched children (9
females, 9 males; mean±SD: age 11.0±3.3 years; body
mass 41.4±14.3 kg; height 146±22 cm) were used as con-
trol reference. All participants gave informed written
consent and the protocol was approved by the local Ethics
Committee.
Instrumentation, protocol and data analysis
Kinematic data were collected using a 9-camera SMART-
D motion capture system (BTS, Milano, Italy) sampling at
200 Hz; two consecutive force plates (Kistler, Winterthur,
Switzerland), with 800 Hz sampling frequency, provided
ground reaction forces.
The total-body LAMB marker set [17] was adopted,
which included 29 retroreflective markers (12 mm
diameter) positioned on the head, upper limbs, trunk,
pelvis and lower limbs.
CMT1A patients were asked to perform 5 trials at
their natural speed (task NW); controls performed 15
trials at different speeds. Control trials whose speed was
inside the speed range observed in patients were selected
as normative reference. Additional tasks included toe-
walking and heel-walking, performed at self-selected
speed and with an effort to maximize the lift of the heel
or toe from the ground during walking.
Data elaboration are fully described in [10] and included:
low pass filtering of markers’ coordinates, computation of
internal joint centers, calculation of lower limb joint kine-
matics and kinetics in all anatomical planes. Specific
values were selected for each variable, according to their
significance and relation to specific clinical signs. For each
patient and side, the average value of selected parameters
and the average pattern of kinematic/kinetic variables
across five trials were computed. Biomechanical data from
right and left sides were not averaged; instead, according
to Burns et al. [18], we focused data analysis on the dom-
inant side or, in case of asymmetry of musculoskeletal
lower limb involvement, on the most affected side at the
baseline evaluation.
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was adopted for both baseline and follow-up evaluation.
Length and mass related parameters were normalized to
body height and weight respectively, as suggested by
several studies [19–21] to remove any effect due to
these two age-dependent factors and thus allowing for a
direct comparison between evaluations made 18 months
apart on growing subjects. The follow-up evaluation
was not performed in children belonging to the control
group, because it was demonstrated that, in normal sub-
jects with mature gait (like those considered in the present
study), gait kinematics and kinetics are characterized by
walking speed, not age [14]. This further supports the use
of speed-matched control data as normative reference.
Parameters
We focused on the same biomechanical parameters
reported in the baseline study: spatio-temporal gait
parameters (gait speed, stride length and cadence), range





Figure 1 Representation, for each CMT1A patient, of changes of para
shapes) and the follow-up (arrow tips) evaluation. The threshold values
0.03 J/kg for AWst, are reported close to the correspondent axes. Double ar
parameter changed significantly, dashed arrow = no parameter changed si
and vertical red lines represent the 5th percentile values in the control subj
respectively, to foot-drop (AROMsw/AROMtot) and push-off deficit (AWst). Th
subgroup in the baseline evaluation: NL=normal-like (squares), FD=foot-dro
subgroup of surgically operated patients is evidenced with a dotted ellipseof disease-related distal deficits (AROMratio and AWst).
AROMratio, calculated as the ankle dorsiflexion ROM
during swing phase divided by the ROM over the whole
gait cycle, is related to foot-drop deficit and is expected to
be smaller in CMT1A patients than in healthy subjects.
AWst is the positive ankle work (calculated as integral of
power curve, normalized to body weight) in stance phase,
thus accounting for the push-off mechanism. The latter
two parameters, related to primary gait deviations of pa-
tients with CMT, were used to classify each patient into
one of the three identified clusters (NL, FD and
FD&POD). Finally, to quantify the reduced capabilities in
more demanding tasks, the difference between the mean
ankle angle of toe- and heel-walking (ATHΔmean) was
computed.
All these parameters showed good reliability in CMT
patients [22].
Normality of parameters distribution was tested with
Shapiro-Wilk Test and was verified for biomechanical
parameters but not for clinical scores, thus significancemeters associated to primary signs between the baseline (empty
of significance change for each parameter, 0.08 for AROMratio and
row = both parameters changed significantly, single arrow = only one
gnificantly. Healthy controls are reported as filled circle. The horizontal
ects’ distribution of the two primary parameters associated,
ose values were used as threshold to define the inclusion in a given
p (circles), FD&POD=foot-drop and push-off deficit (triangles). The
.
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was tested with parametric tests (paired T-test) for the
former and with non parametric tests (Wilcoxon Signed
Rank test) for the latter. Non parametric Spearman’s
Rho coefficient was computed to test for correlation be-
tween baseline-to-follow-up changes of biomechanical
parameters and of clinical scores. To assess significance
of mean differences between controls and the whole
group of CMT1A patients T-test was applied on bio-
mechanical parameters. Finally, comparisons among
controls and CMT1A sub-groups were performed with
ANOVA and Tukey’s HSD post-hoc for biomechanical
parameters and with Kruskas-Wallis ANOVA and
Nemenyi-Damico-Wolfe-Dunn post-hoc for clinical
scores. All tests have been performed with R software
ver. R2.14.1 (www.R-project.org) setting a significance
level of 0.05, with a proper correction for multiple com-
parisons in post-hoc tests.Table 1 Clinical scores and kinematic/kinetic parameters at th
Controls CMT1A-all
(N=18) (N=16)
Session Baseline Follow-up Ba
Age [years] 11.0(3.3) 11.7(2.9) 13.2(2.9) 11
Weight [kg] 41.4(14.3) 40.4(10.5) 45.9(11.3) 37.
Height [cm] 146(22) 148(15) 158(14) 14
Clinical scores
CMTES - 3.4(2.3) 4.8(3.4)# 2.




1.1(0.1) 1.2(0.1) 1.1(0.1) 1.
Gait speed/BH
[%BH s-1]
77.0(7.0) 78.7(9.8) 74.7(13.3) 79.
Cadence
[steps min-1]
116(11) 117(10) 115(12) 11
Stride length
[m]
1.2(0.2) 1.2(0.1) 1.2(0.1) 1.
Stride length/
BH [%BH]
79.8(4.1) 80.7(5.8) 78.3(7.9)# 82
AROMratio 0.65(0.09) 0.55(0.20)
* 0.51(0.21) 0.7





The table shows clinical scores and kinematic/kinetic parameters at the baseline an
for the different subgroups (NL normal-like, FD Foot-drop, FD&POD Foot-drop and P
Data are given in terms of mean and SD (in parentheses).
The two parameters used to classify patients into sub-groups based on the baseline
deficit index). BH Body height, Toe-heel Toe- and Heel-walking trials. See the text (se
* Significant differences between controls and CMT1A-all group at baseline (p<0.05
a Significant differences between controls and CMT1A sub-groups at baseline (p<0.
b Significant differences between NL and FD or FD&POD group at baseline (p<0.05
c Significant differences between FD and FD&POD group at baseline (p<0.05 ANOV
# Significant differences between baseline and follow-up evaluation (p<0.05 paired
clinical scores).At individual level, a change greater than the SEM value
evaluated for each parameter in a test-retest study on
CMT patients (0.08 for AROMratio and 0.03 J/kg for AWst;
[10,22]) was considered significant. To classify if a patient
moved from the original cluster assigned in the baseline
evaluation to another, a threshold correspondent to the 5th
percentile on the distribution of the relevant parameter in
the controls’ group (AROMratio = 0.553 for the foot-drop
deficit and AWst = 0.218 J/kg for the push-off deficit) was
adopted (see Figure 1).Results
Since the focus of the present paper is on the follow-up,
we will not discuss here the comparison between con-
trols and CMT1A patients in the baseline evaluation;
however, significant differences, which were discussed in
a previous paper [10], are reported in Table 1 as well.e baseline and follow-up evaluation
NL subgroup FD subgroup FD&POD subgroup
(N=7) (N=6) (N=3)
seline Follow-up Baseline Follow-up Baseline Follow-up
.6(2.4) 13.0(2.4) 12.0(3.0) 13.6(2.9) 11.5(4.7) 12.9(4.8)
7(12.1) 46.1(15.7) 44.3(8.8) 47.4(6.3) 39.1(10.7) 42.8(10.1)
5(16) 156(17) 152(12) 163(8) 147(22) 150(17)
4(1.3) 3.5(2.1) 3.5(2.8) 5.2(4.3) 5.3(2.3) 7.0(4.3)
4(0.8) 2.4(1.0) 1.7(0.8) 2.0(1.1) 3.3(0.6) 3.3(0.6)
1(0.1) 1.2(0.1) 1.2(0.1) 1.1(0.1) 1.0(0.1) 1.0(0.2)
2(12.4) 77.7(13.9) 81.6(6.9) 72.6(9.1)# 71.8(6.2) 70.8(20.4)
5(13) 117(13) 119(7) 112(9)# 117(7) 117(19)
2(0.1) 1.3(0.1)# 1.2(0.1) 1.2(0.0) 1.1(0.1) 1.1(0.1)
.0(5.0) 81.0(6.8) 82.1(5.3) 78.6(5.9) 75.1(6.7) 71.7(12.4)
4(0.09) 0.63(0.18) 0.46(0.04)a,b 0.47(0.20) 0.26(0.03)a,b,c 0.27(0.09)
0(0.06) 0.29(0.05) 0.31(0.04) 0.30(0.04) 0.17(0.02)a 0.19(0.03)
.7(7.6) 20.0(6.2) 17.7(5.9)a 15.7(7.8) 14.3(7.5)a 13.4(3.2)
d follow-up evaluation for the whole group of CMT patients (CMT1A-all) and
ush-off Deficit). Data from the control group are reported in the first column.
evaluation are evidenced in bold (AROMratio foot-drop index, AWst push-off
ction Methods) for the meaning of biomechanical parameters.
T-test).
05 ANOVA and Tukey’s HSD post-hoc).
ANOVA and Tukey’s HSD post-hoc).
A and Tukey’s HSD post-hoc).
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Figure 2 (See legend on next page.)
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Figure 2 Pattern of sagittal angular displacement (left panel) and power (right panel) of hip and ankle joints during natural walking
for each CMT1A subgroup based on clusterization in the baseline evaluation: comparison between inter-subject average profiles at
baseline (solid line) and follow-up (dotted line) evaluations. Letters ‘A’ and ‘H’ indicate the main changes (see text). Data of the healthy
group are reported as control reference (grey area, mean ±1SD). NL: normal-like, FD: foot-drop, FD&POD: foot-drop and push-off deficit.
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showed that overall, a significant worsening of CMTES
score (from 3.4±2.3 to 4.8±3.4, p<0.05) and a reduction
of stride length of gait (80.9±5.9 to 78.4±8.1%BH,
p<0.05) occurred between the baseline and the follow-up
evaluation. No other significant difference between the
two sessions could be identified. However, by inspecting
the data of individual patients, different behaviors were
observed as shown in Figure 1, which reports the indi-
vidual changes of position in the plan of primary sign
parameters (AROMratio and AWst). It resulted that all but
one of the non-operated patients significantly changed at
least one of the two parameters: 8 patients changed only
one parameter and 7 both. Specifically, 11 participants
significantly worsened at least one parameter (2 worsened
both parameters while 5 improved the other parameter)
and 9 significantly improved one parameter.
As regards clinical scores, 11 out of 16 participants did
not change ONLS score and 4 did not change CMTES
score. A change of 1 (minimum detectable change at
individual level) in ONLS and CMTES score was found
in 3 and 6 participants, respectively. No correlation (Rho
absolute value always smaller than 0.5, p-value always
greater than 0.09) between changes in biomechanical
and clinical indexes was identified.
At sub-group level (see Table 1), patients originally
belonging to the NL subgroup showed a trend towards
a worsening of foot-drop deficit (−15%, from 0.74 to
0.63, p=0.12). Specifically, two patients (indicated with
G and Q in Figure 1) showed at follow-up a foot-drop
which moved them to the FD subgroup while the other
five showed changes in primary parameters which were
not enough to exit them from the normal-like subgroup.
FD patients, as a group, significantly decreased gait
velocity and cadence but did not change primary signs,
although two opposite behaviors could be identified:
three participants increased foot-drop index (patients B,
I, N) allowing them to be re-classified into the NL sub-
group, the other three worsened foot-drop and/or push-
off deficit (A, K, O) although not moving to the worst
FD&POD subgroup. Finally, non-operated FD&POD
patients (D, F, H) did not change their abnormal condi-
tion as a sub-group (see Table 1). No significant changes
in clinical scores were showed by any sub-group.
In Figure 2 the time course of ankle and hip sagittal
angle and power during natural walking trials are
reported for all non-operated CMT1A patients, grouped
according to the baseline evaluation. For each subgroupthe comparison between inter-subject average profiles
at baseline and follow-up evaluations are shown, to-
gether with the control range (grey area, mean ±1SD).
The most significant changes in average joint kine-
matic/kinetic profiles between baseline and follow-up
evaluations occurred at:
1) ankle joint, which slightly worsened foot-drop
(indicated with ‘A’ in Figure 2) in all subgroups;
2) hip joint angle, which moved towards exaggerated
flexion (H) in FD&POD patients;
As regards toe- and heel-walking trials, shown in
Figure 3, all CMT1A subgroups showed abnormal
ankle angle patterns at the baseline, including the
NL subgroup who showed a normal pattern during
natural walking but a less dorsiflexed ankle during
heel-walking. In the follow-up session a worsening in
heel-walking was shown by FD subgroup and in toe-
walking by FD&POD subgroup (indicated by arrows in
Figure 3). As a consequence, all sub-groups showed a
trend towards a worsening of the ATHΔmean in the follow-
up evaluation with respect to baseline, although no one
reached statistical significance (see Table 1, last row).
Due to the small number of patients who underwent
foot surgery between the baseline and the follow-up
evaluation, their results are here presented only descrip-
tively. Specific surgical procedures performed on the
three operated subjects were calcaneal osteotomy, exten-
sion osteotomy of the 1st metatarsal head, and/or plantar
fascia release.
All 3 patients improved the push-off index (see
Figure 1), one of whom (patient M) improved also the
foot-drop index and moved from the FD&POD to the
normal-like subgroup. Conversely, ONLS clinical score
did not change and CMTES worsened in all cases with a
change of 1, 3 and 4 points respectively in patient M,
E and L.
Some changes in gait kinematics and kinetics were
common to all 3 operated patients, as shown by inter-
subject average profiles reported in Figure 4. Specifically
they showed:
– improvement of dorsiflexion during the whole gait
cycle (A1) and increase of power production at
push-off (A2);
– improvement of knee joint kinematic and kinetic
profiles in terms of knee yielding normalization (K1)
Natural walking Heel walking Toe walking
NL group: heel-and toe-walking
Natural walking Heel walking Toe walking
FD group: heel-and toe-walking
Natural walking Heel walking Toe walking
FD&POD group: heel-and toe-walking
Figure 3 (See legend on next page.)
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Figure 3 Patterns of ankle flexion-extension angle during natural walking (left panel), heel-walking (center panel) and toe-walking
(right panel) for each CMT1A subgroup: comparison between inter-subject average profiles at baseline (solid line) and follow-up
(dotted line) evaluations. Data of the healthy group is reported as control reference (grey area, mean ±1SD). Arrows show the main changes
between baseline and follow-up evaluations in heel- and toe-walking.
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mid stance (K2) and initial swing (K3);
– decrease of hip power exaggerated peak values at
early/mid stance (H1) and initial swing (H2);
– improvement of dorsiflexion in heel-walking and a
reduction of plantarflexion in toe-walking.
Discussion
Due to the very slowly rate of progression of the disease,
monitoring the changes occurring in locomotor func-
tions on patients with CMT1A is a challenging task. In a
natural history study of 72 adult patients with CMT1A
disease Shy et al. [12] reported an average CMTNS rate
of worsening of 0.686 points per year. Subsequent stud-
ies found smaller values of 0.5 [23] and 0.3 [13] points
per year. Finally, a recent 2 years clinical trial [24] found
an average worsening of 0.23 points per year in the pla-
cebo group of 133 adult patients with CMT1A. Consid-
ering that the worst score of CMTNS is 36 points, it
means that the average annual rate of change reported
in literature ranges between 0.64% and 1.91% of maximal
score. These small values are a concern for natural his-
tory studies and clinical trials in CMT1A disease, par-
ticularly in young patients where possible disease-related
changes might be influenced by growing. Indeed, specific
CMT pediatric score (CMTPedS) is being developed [7].
Results of the present study on children with CMT1A
showed that after 18 months, besides a worsening of
CMTES score, a significant reduction in stride length
was identified through gait analysis in non-operated pa-
tients. Moreover, at individual level, all but one patients
significantly changed at least one of the biomechanical
parameters related to disease-specific distal deficits (i.e.
foot-drop and push-off deficit) used to classify gait pat-
terns, while clinical scores either did not change (ONLS)
or only minimally worsened (CMTES) for most of the
participants. This different degree of sensitivity between
clinical and instrumental evaluation, may explain why
we did not find any correlation between changes in bio-
mechanical parameters and changes in clinical scores.
Although the group of non-operated CMT1A partici-
pants showed a slight reduction of stride length, indicat-
ing a general tendency of locomotor function to worsen,
at individual level different behaviors were found: some
patients clearly worsened their gait pattern in term of
foot-drop and/or push-off deficit, other showed an im-
provement that, in three cases, even produced a reduc-
tion of foot-drop enough to move them from the FDsubgroup to the normal-like subgroup. A considerable
phenotypic variability within CMT1A is already known
[1]: while some patients develop relevant weakness,
require walking aids or even exceptionally become chair-
bound, others are completely asymptomatic and un-
aware of being affected. Our results seem to indicate
that, in young patients, a considerable inter-subject vari-
ability does not only characterize the degree of severity,
but also its rate of progression, which we found quite
different in our cohort of patients, with some patients
even showing a walking deficit reduction in a 18 months
time period. This result is supported by recent longitu-
dinal data (derived from [7]) on 11 young patients with
CMT1A, 5 of whom showed, after 1-year period, a de-
crease of disability as measured by CMTEPedS. Re-
searches on genetic and/or environmental factors which
influence disease severity are already in progress [1] and,
to this aim, the availability of objective and sensitive in-
dexes of disease-related deficit, like those presented in
the present paper, is a crucial factor.
Although the number of operated patients is too small
to conclude about efficacy of surgery, it is worth to men-
tion that all of them showed a significant improvement
in the push-off AWst parameter. Since these patients ori-
ginally belonged to the most severe group (FD&POD)
and showed the worst push-off deficit within the entire
group, this result seems to indicate a positive effect of
surgery on push-off, crucial for walking efficiency. A
possible explanation of this effect relies on the surgical
correction of foot deformities at calcaneal, plantar and/or
metatarsal level, which allows for a more physiological tra-
jectory of the center of pressure and a lengthening of the
level arm of ground reaction force with respect to the
ankle at terminal stance. Indeed, at follow-up this group
showed also a proximal improvement, secondary to distal
surgery, in kinematic and kinetic profiles of knee and hip
joints during natural walking. Finally, the release of plantar
fascia might explain the reduced plantarflexion observed
during toe-walking, where a stiff mid-foot is required.
Apart from surgery, no other factors (i.e. age, time
since symptom onset, disease severity at the baseline,
growth, participation in rehabilitation program or in
sport activity) were identified to explain improvements
in locomotor functions. However, we cannot be conclusive
on the last mentioned factor, since the cohort of patients
was coming from the whole Italian territory, therefore
their therapeutic regimen and/or physical activity program
















   
   
   


















   


















































   





Surgically operated group: natural walking















   
   
   




















   
   
   



















   






Figure 4 (See legend on next page.)
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Figure 4 Patterns of sagittal angular displacement (left panels) and power (right panels) of hip and ankle joints during natural walking
for the subgroup of surgically operated CMT1A children: comparison between inter-subject average profiles at baseline (solid line)
and follow-up (dotted line) evaluations. Letters ‘A’, ‘H’ and ‘K’ indicate the main changes (see text). The bottom panels show, for the same
subgroup of patients, the patterns of ankle flexion-extension angle during heel-walking (left panel) and toe-walking (right panel). Arrows show
the shift of ankle angular pattern between baseline and follow-up evaluations. Data of the healthy group are reported as control reference (grey
area, mean ±1SD).
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ized protocols for rehabilitation in CMT patients are still
lacking, particularly for paediatric age. Further studies fo-
cused on those factors are needed to elucidate their effects
on motor symptoms.
We found a rate of worsening of CMTES and ONLS
of, respectively, 0.93 and 0.33 points per year, corre-
sponding to 3.3% and 2.7% of maximal score, thus
greater than those reported in literature for adult pa-
tients with CMT1A [12,13,23,24]. This might be due to
the younger age of our sample or to other uncontrolled
bias in patient selection, considering the relatively small
size of our series, therefore results of the present study
cannot be generalized to the entire CMT1A population.
Another limitation of the present study, linked to the
small sample size enrolled, is the underpowered sub-
group statistical analysis that may have hidden differences
between baseline and follow-up or among sub-groups.
Finally, it is to be underlined that some of the changes
in gait patterns observed in young CMT patients in 18
months, might not be considered only as a direct conse-
quence of disease progression, since the development of
compensatory strategies and/or other factors associated to
a possible atypical maturation of gait in presence of motor
deficit cannot be excluded. In fact, while foot-drop wors-
ening is reasonably the effect of disease-related weakening
of dorsi-flexor muscles, push-off deficit may be attributed,
in addition to weakening of plantar-flexors, also to a com-
pensatory strategy aimed to find a trade-off between pro-
pulsive action, balance requirements and margin of safety
during locomotion. Likewise, the trend towards exagger-
ated hip flexion during swing, showed by FD&POD pa-
tients at follow-up, can be explained as the development
of a compensation to allow for foot clearance despite the
worsening of foot-drop deficit. In this view, the specific
analysis provided by instrumented gait analysis at different
segments and joints is a valid tool for a comprehensive
evaluation of locomotor function.
The large inter-subject variability on disease severity
and on its rate of progression found in our young CMT
patients, together with the possibility to distinguish pri-
mary signs from compensatory strategies, strengthen the
use of gait analysis as a support for clinical decision
making in the management of motor deficits in these pa-
tients: the knowledge of joint-specific locomotor abnor-
malities is expected to help in tailoring rehabilitationexercises, planning ankle-foot surgery and/or customiz-
ing lower limb orthosis for each individual.
Conclusions
Our results showed that:
1) in young CMT1A patients subtle changes in gait
parameters and kinematics/kinetics profiles,
occurring in a 18 months period, can be identified
instrumentally;
2) such changes show a large inter-subject variability,
with some patients even improving their walking
pattern, and are not correlated with changes in
clinical scores; this result strengthens the use of gait
analysis as a support for clinical decision making in
the management of motor deficits in these patients;
3) there are anecdotal indications that corrective
surgery of foot deformities may improve the push-
off phase of gait, with secondary positive effects also
at proximal joints.
Future studies with larger sample of patients and lon-
ger follow-up might verify if outcome measures provided
by instrumented gait analysis are more sensitive and reli-
able than clinical scores for natural history studies and
randomized clinical trials.
Endnotes
aCMTES (CMT Examination Score) is the clinical
component of the CMT Neuropathy Score (CMTNS), a
validated composite scale for CMT [4], and has a score
ranging from 0 (normal) to 28 (worst).
bONLS (Overall Neuropathy Limitations Scale) is a
scale to evaluate activity limitations in peripheral neur-
opathy [25] and has a score ranging from 0 (normal) to
12 (worst).
Abbreviations
CMT: Charcot Marie tooth; CMT1A: Charcot Marie tooth type 1A;
CMTES: Charcot Marie tooth examination score; CMTNS: Charcot Marie tooth
neuropathy score; ONLS: Overall neuropathy limitation scale; NL: Normal-like;
FD: Foot-drop; FD&POD: Foot-drop and push-off deficit; ROM: Range of
motion; AROMratio: Ankle ROM ratio, index related to foot-drop deficit;
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